Efficacy

Xpovio (Selinexor) Efficacy in Multiple Myeloma

Xpovio (selinexor) is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound that has shown efficacy in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. The U.S. Food and Drug Administration (FDA) approved Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Clinical trials have demonstrated that Xpovio, in combination with dexamethasone, can lead to a significant reduction in tumor burden in a subset of these heavily pretreated patients.

The approval of Xpovio for this indication was based on the results of the STORM study, a Phase 2b clinical trial that evaluated the drug's efficacy in patients with RRMM. In this study, Xpovio demonstrated a meaningful overall response rate (ORR), which is the proportion of patients with a partial or complete response to the therapy. The ORR observed in the trial provided evidence that Xpovio could offer a therapeutic benefit to patients who have limited treatment options due to the advanced nature of their disease.

Elrexfio (Elranatamab-bcmm) Efficacy in Multiple Myeloma

Elrexfio (elranatamab-bcmm), previously known as PF-06863135, is an investigational bispecific antibody that targets BCMA (B-cell maturation antigen) and CD3 on T cells. BCMA is commonly expressed on the surface of multiple myeloma cells. Elrexfio is designed to redirect T cells to engage and eliminate BCMA-expressing myeloma cells. While Elrexfio is not yet approved for use, it has shown promise in early clinical trials for the treatment of multiple myeloma.

In the ongoing clinical trials, Elrexfio has demonstrated an ability to induce responses in patients with relapsed or refractory multiple myeloma. The data from these trials suggest that Elrexfio can produce deep and durable responses, with a number of patients achieving a very good partial response (VGPR) or better. The efficacy of Elrexfio as a monotherapy is being further investigated in larger, more advanced clinical trials to confirm its potential benefits and to support its application for regulatory approval.